1988
THE FREQUENCY OF EPSTEIN-BARR VIRUS INFECTION AND ASSOCIATED LYMPHOPROLIFERATIVE SYNDROME AFTER TRANSPLANTATION AND ITS MANIFESTATIONS IN CHILDREN
Ho M, Jaffe R, Miller G, Breinig M, Dummer J, Makowka L, Atchison R, Karrer F, Nalesnik M, Starzl T. THE FREQUENCY OF EPSTEIN-BARR VIRUS INFECTION AND ASSOCIATED LYMPHOPROLIFERATIVE SYNDROME AFTER TRANSPLANTATION AND ITS MANIFESTATIONS IN CHILDREN. Transplantation 1988, 45: 719-726. PMID: 2833828, PMCID: PMC2993427, DOI: 10.1097/00007890-198804000-00011.Peer-Reviewed Original ResearchConceptsLymphoproliferative syndromePrimary infectionEBV infectionTransplant recipientsEpstein-Barr virus infectionMonoclonal B-cell lymphomaPediatric liver recipientsPrimary EBV infectionPediatric transplant recipientsEpstein-Barr virusEBV nuclear antigenB-cell lymphomaLiver recipientsPediatric EBVCyclosporine monitoringEBV DNAClinical typesPediatric casesSecond syndromeVirus infectionCell lymphomaAdditional casesGreater riskInfectionNuclear antigen
1987
Novel nuclear antigens recognized by human sera in lymphocytes latently infected by Epstein-Barr virus
Rowe D, Farrell P, Miller G. Novel nuclear antigens recognized by human sera in lymphocytes latently infected by Epstein-Barr virus. Virology 1987, 156: 153-162. PMID: 3027963, DOI: 10.1016/0042-6822(87)90446-6.Peer-Reviewed Original ResearchConceptsEBNA seraAntigen complexX50-7Immortalization of lymphocytesEpstein-Barr virusEBNA INovel nuclear antigenIV groupNew antigensNuclear antigenLymphocytesCell clonesWestern immunoblottingSerumCell linesEBVAntigenMolecular weight proteinsHuman serumHigh molecular weight proteinsRajiVirusViral genomeGroupWeight proteins
1985
Identification and expression of a nuclear antigen from the genomic region of the Jijoye strain of Epstein-Barr virus that is missing in its nonimmortalizing deletion mutant, P3HR-1.
Rowe D, Heston L, Metlay J, Miller G. Identification and expression of a nuclear antigen from the genomic region of the Jijoye strain of Epstein-Barr virus that is missing in its nonimmortalizing deletion mutant, P3HR-1. Proceedings Of The National Academy Of Sciences Of The United States Of America 1985, 82: 7429-7433. PMID: 2997790, PMCID: PMC391358, DOI: 10.1073/pnas.82.21.7429.Peer-Reviewed Original ResearchConceptsChronic active EBV infectionActive EBV infectionEpstein-Barr virusJijoye strainEBV infectionEBV DNACertain patientsP3HR-1Human antiseraVirus strainsNuclear antigenHr-1JijoyeVirus deletion mutantsLtk- cellsMouse Ltk- cellsImmortalization processPatientsGene transferNeoantigensLymphocytesInfectionAntigenAntibody Responses to Two Epstein-Barr Virus Nuclear Antigens Defined by Gene Transfer
Miller G, Grogan E, Fischer D, Niederman J, Schooley R, Henle W, Lenoir G, Liu C. Antibody Responses to Two Epstein-Barr Virus Nuclear Antigens Defined by Gene Transfer. New England Journal Of Medicine 1985, 312: 750-755. PMID: 2983211, DOI: 10.1056/nejm198503213121204.Peer-Reviewed Original ResearchConceptsChronic active EBV infectionActive EBV infectionEBV infectionNuclear antigenEpstein-Barr virus nuclear antigenEpstein-Barr virus DNAEBV-seropositive subjectsAbnormal immune responseAssociation of EBVNorth African patientsAbsence of antibodiesSuch patientsAfrican patientsSerologic studiesImmune responseNasopharyngeal carcinomaLymphoid cellsPatientsViral gene productsSpecific viral gene productsViral mutationsSerologic reactionsAntigenSerum samplesM antigenConstitutive expression of Epstein-Barr virus-encoded RNAs and nuclear antigen during latency and after induction of Epstein-Barr virus replication
Weigel R, Fischer D, Heston L, Miller G. Constitutive expression of Epstein-Barr virus-encoded RNAs and nuclear antigen during latency and after induction of Epstein-Barr virus replication. Journal Of Virology 1985, 53: 254-259. PMID: 2981344, PMCID: PMC255024, DOI: 10.1128/jvi.53.1.254-259.1985.Peer-Reviewed Original ResearchConceptsEpstein-Barr virus-encoded RNAVirus-encoded RNAEpstein-Barr virus replicationNuclear antigenEpstein-Barr virusLatent gene productsEpstein-Barr virus gene productsHR-1 cellsVirus gene productsViral variantsVirus replicationAntigen mRNAAbsence of inductionViral DNAAntigenInductionMethod of inductionPhorbol esterViral polypeptidesViral transcriptsGene productsCytoplasmic abundanceExpressionConstitutive expressionConstitutive levels
1979
Experimental Carcinogenicity by the Virus In Vivo
Miller G. Experimental Carcinogenicity by the Virus In Vivo. 1979, 351-372. DOI: 10.1007/978-3-642-67236-1_16.Peer-Reviewed Original ResearchEpstein-Barr virusEBV nuclear antigenBurkitt's lymphomaEBV DNA copiesHuman EBV infectionEBV infectionLymphoid folliclesLymphoproliferative syndromeMalignant diseaseGerminal centersLymphoid neoplasmsNew World primatesNuclear antigenSpectrum of responsesOwl monkeysLymphomaInfectionExperimental carcinogenicityVirusDNA copiesNeoplasmsSyndromeTumorsAntigenDisease
1978
Radiobiological Inactivation of Epstein-Barr Virus
Henderson E, Heston L, Grogan E, Miller G. Radiobiological Inactivation of Epstein-Barr Virus. Journal Of Virology 1978, 25: 51-59. PMID: 202757, PMCID: PMC353900, DOI: 10.1128/jvi.25.1.51-59.1978.Peer-Reviewed Original ResearchConceptsEpstein-Barr virusEarly antigen inductionAntigen inductionStrain of EBVAbility of EBVHerpes simplex virus type 1B95-8 virusSimplex virus type 1Herpes simplex virusVirus type 1X-irradiationCell DNA synthesisHost cell DNA synthesisLymphoid cell linesEBV genomeB95-8EBV transformationSimplex virusPlaque formationType 1Nuclear antigenMechanisms of repairPrimary lymphocytesCell clonesDose of irradiation
1974
OROPHARYNGEAL EXCRETION OF EPSTEIN-BARR VIRUS BY RENAL TRANSPLANT RECIPIENTS AND OTHER PATIENTS TREATED WITH IMMUNOSUPPRESSIVE DRUGS
Strauch B, Siegel N, Andrews L, Miller G. OROPHARYNGEAL EXCRETION OF EPSTEIN-BARR VIRUS BY RENAL TRANSPLANT RECIPIENTS AND OTHER PATIENTS TREATED WITH IMMUNOSUPPRESSIVE DRUGS. The Lancet 1974, 303: 234-237. PMID: 4130246, DOI: 10.1016/s0140-6736(74)92546-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, ViralAzathioprineCarrier StateChildChild, PreschoolFemaleFluorescent Antibody TechniqueHerpesvirus 4, HumanHumansImmunity, CellularImmunosuppressive AgentsKidney TransplantationLeukocytesMaleMiddle AgedMouthMucusPharynxPostoperative CarePrednisoneProspective StudiesTherapeutic IrrigationTransplantation, HomologousConceptsEpstein-Barr virusImmunosuppressive drugsRenal homograftsRenal transplant recipientsOropharyngeal excretionShed virusVirus excretorsImmunosuppressive therapySeropositive patientsTransplant recipientsChronic uraemiaThroat washingsVirus 8Seropositive individualsThroat samplesVirus sheddingVirus infectionPatientsNuclear antigenHealthy staffLong-term proliferationDrugsVirusHomograftsTransplantationExpression of Epstein-Barr viral capsid, complement fixing, and nuclear antigens in stationary and exponential phase cultures.
Miller G, Heston L. Expression of Epstein-Barr viral capsid, complement fixing, and nuclear antigens in stationary and exponential phase cultures. The Yale Journal Of Biology And Medicine 1974, 47: 123-35. PMID: 4372815, PMCID: PMC2596417.Peer-Reviewed Original ResearchConceptsViral capsid antigenEpstein-Barr viralCapsid antigenNuclear antigenComplement fixingContinuous lymphoblastoid cell linesEpstein-Barr viral capsidViable cellsContent of antigensProportion of cellsLymphocyte transformationAnticomplement immunofluorescenceLymphoblastoid cell linesComplement-fixing (CF) antigenCell subpopulationsComplement fixationAntigenAntigen complexIntranuclear antigensProducer linesCell linesCells